1	NF1 regulates mesenchymal glioblastoma plasticity and aggressiveness
2	through the AP-1 transcription factor FOSL1
3	
4	Carolina Marques ¹ , Thomas Unterkircher ² , Paula Kroon ¹ , Annalisa Izzo ² , Gaetano
5	Gargiulo ³ , Eva Kling ² , Oliver Schnell ² , Sven Nelander ⁴ , Erwin F. Wagner ^{5,6,7} , Latifa
6	Bakiri ^{5,7} , Maria Stella Carro ^{2*} and Massimo Squatrito ^{1*}
7	
8	¹ Seve Ballesteros Foundation Brain Tumor Group, Spanish National Cancer Research
9	Centre, CNIO, 28029 Madrid, Spain.
10	² Department of Neurosurgery, Faculty of Medicine Freiburg, D-79106 Freiburg,
11	Germany.
12	³ Max-Delbrück-Center for Molecular Medicine (MDC), Robert-Rössle-Str. 10, 13092
13	Berlin, Germany.
14	⁴ Dept of Immunology, Genetics and Pathology and Science for Life Laboratory,
15	Uppsala University, Rudbecklaboratoriet, SE-751 85 Uppsala, Sweden.
16	⁵ Genes, Development, and Disease Group, Spanish National Cancer Research Centre,
17	CNIO, 28029 Madrid, Spain.
18	⁶ Dermatology Department, Medical University of Vienna, A-1090 Vienna, Austria.
19	⁷ Laboratory Medicine Department, Medical University of Vienna, A-1090 Vienna,
20	Austria.
21	
22	* Correspondence: maria.carro@uniklinik-freiburg.de; msquatrito@cnio.es
23	
24	Lead contact: Massimo Squatrito

25 Summary

26 The molecular basis underlying Glioblastoma (GBM) heterogeneity and plasticity are not 27 fully understood. Using transcriptomic data of patient-derived brain tumor stem cell lines 28 (BTSCs), classified based on GBM-intrinsic signatures, we identify the AP-1 29 transcription factor FOSL1 as a master regulator of the mesenchymal (MES) subtype. We 30 provide a mechanistic basis to the role of the Neurofibromatosis type 1 gene (NF1), a 31 negative regulator of the RAS/MAPK pathway, in GBM mesenchymal transformation 32 through the modulation of FOSL1 expression. Depletion of FOSL1 in NF1-mutant human 33 BTSCs and Kras-mutant mouse neural stem cells results in loss of the mesenchymal gene 34 signature, reduction in stem cell properties and in vivo tumorigenic potential. Our data 35 demonstrate that FOSL1 controls GBM plasticity and aggressiveness in response to NF1 36 alterations.

37

38 Keywords

39 GBM, Mesenchymal, NF1, FOSL1, FRA-1, master regulator

40

41 Significance

42 Glioblastoma (GBM) is a very heterogenous disease for which multiple transcriptional 43 subtypes have been described. Among these subtypes, the Mesenchymal (MES) GBMs 44 have the worst prognosis. Here we provide the first causal evidence linking 45 Neurofibromatosis type 1 gene (NF1) signalling and the acquisition of a MES gene expression program through the regulation of the AP-1 transcription factor FOSL1. Using 46 47 patient expression datasets, combined with in vitro and in vivo gain- and loss- of function 48 mouse models, we show that FOSL1 is an important modulator of GBM that is required 49 and sufficient for the activation of a MES program. Our work sheds light on the 50 mechanisms that control the tumorigenicity of the most aggressive adult brain tumor type.

51 Introduction

52 Glioblastoma (GBM), the most common and aggressive primary brain tumor in 53 adults, is characterized by high molecular and cellular inter- and intra-tumoral 54 heterogeneity. Large-scale sequencing approaches have evidenced how concurrent 55 perturbations of cell cycle regulators, growth and survival pathways, mediated by 56 RAS/MAPK and PI3K/AKT signaling, play a significant role in driving adult GBMs 57 (Brennan et al., 2013; The Cancer Genome Atlas Research Network, 2008; Verhaak et 58 al., 2010). Moreover, various studies have classified GBM in different subtypes, using 59 transcriptional profiling, being now the Proneural (PN), Classical (CL) and Mesenchymal 60 (MES) the most widely accepted (Phillips et al., 2006; Verhaak et al., 2010; Wang et al., 61 2017).

62 Patients with the MES subtype tend to have worse survival rates compared to other 63 subtypes, both in the primary and recurrent tumor settings (Wang et al., 2017). The main 64 driver genetic alteration – Neurofibromatosis type 1 gene (NF1) copy number loss or 65 mutation - and important regulators of the MES subtype, such as STAT3, CEBPB and 66 TAZ, have been identified (Bhat et al., 2011; Carro et al., 2010; Verhaak et al., 2010). 67 Nevertheless, the mechanisms of regulation of MES GBMs are still not fully understood. For example, whether the MES transcriptional signature is controlled through tumor cell-68 69 intrinsic mechanisms or influenced by the tumor microenvironment (TME) is still an 70 unsolved question. In fact, the critical contribution of the TME adds another layer of 71 complexity to MES GBMs. Tumors from this subtype are highly infiltrated by non-72 neoplastic cells, as compared to PN and CL subtypes (Wang et al., 2017). Additionally, 73 MES tumors express high levels of angiogenic markers and exhibit high levels of necrosis 74 (Cooper et al., 2012).

75 Even though each subtype is associated with specific genetic alterations, there is 76 a considerable plasticity among them: different subtypes co-exist in the same tumors and 77 shifts in subtypes can occur over time (Patel et al., 2014; Sottoriva et al., 2013). This 78 plasticity may be explained by acquisition of new genetic and epigenetic abnormalities, 79 by stem-like reprogramming or by clonal variation (Fedele et al., 2019). It is also not fully 80 understood whether the distinct subtypes evolve from a common glioma precursor 81 (Ozawa et al., 2014). For instance, PN tumors often switch phenotype to MES upon 82 recurrence, and treatment also increases the mesenchymal gene signature, suggesting that 83 MES transition, or epithelial to mesenchymal (EMT)-like, in GBM is associated with 84 tumor progression and therapy resistance (Bhat et al., 2013; Halliday et al., 2014; Phillips

et al., 2006). Yet, the frequency and relevance of this EMT-like phenomenon in glioma progression remains unclear. EMT has also been associated with stemness in other cancers (Mani et al., 2008; Tam and Weinberg, 2013; Ye et al., 2015). Glioma stem cells (GSCs) share features with normal neural stem cells (NSCs) such as self-renewal and ability to differentiate into distinct cellular lineages (astrocytes, oligodendrocytes and neurons) but are thought to be the responsible for tumor relapse, given their ability to repopulate tumors and their resistance to treatment (Bao et al., 2006; Chen et al., 2012).

FOSL1, that encodes FRA-1, is an AP-1 transcription factor with prognostic value
in different epithelial tumors, where its overexpression correlates with tumor progression
or worse patient survival (Chiappetta et al., 2007; Gao et al., 2017; Usui et al., 2012;
Vallejo et al., 2017; Wu et al., 2015; Xu et al., 2017). Moreover, the role of *FOSL1* in
EMT has been documented in breast and colorectal cancers (Andreolas et al., 2008; Bakiri
et al., 2015; Diesch et al., 2014; Tam et al., 2013). In GBM, it has been shown that *FOSL1*modulates *in vitro* glioma cell malignancy (Debinski and Gibo, 2005).

Here we report that *NF1* loss, by increasing RAS/MAPK activity, modulates *FOSL1* expression which in turn plays a central function in the regulation of MES GBM. Using a surrogate mouse model of MES GBM and patient-derived MES brain tumor stem cells (BTSCs), we show that *FOSL1* is responsible for sustaining cell growth *in vitro* and *in vivo*, and for the maintenance of stem-like properties. We propose that *FOSL1* is an important regulator of GBM stemness, MES features and plasticity, controlling an EMTlike process with therapeutically relevant implications.

106

107 **Results**

108 FOSL1 is a master regulator of the MES subtype

109 To study the tumor cell-intrinsic signaling pathways that modulate the GBM 110 expression subtypes we assembled a collection of transcriptomic data (both expression 111 arrays and RNA-sequencing) of 115 samples derived from 87 independent BTSC lines: 112 24 newly generated at Freiburg Medical Center, 44 from GSE119834 (Mack et al., 2019), 113 10 from GSE67089 (Mao et al., 2013) and 9 from GSE8049 (Günther et al., 2008). 114 Samples were then classified according to the previously reported 50-gene glioma-115 intrinsic transcriptional subtype signatures and the single sample gene set enrichment 116 analysis (ssGSEA)-based equivalent distribution resampling classification strategy 117 (Wang et al., 2017). Overall, 39% of the samples were identified as CL, 41% as MES and 118 20% as PN (Table S1). Principal component analysis showed a large overlap of the

transcription profile among CL and PN BTSCs while most of the MES BTSCs appeared as a separate group (Figure 1A). Differential gene expression analysis comparing MES versus Non-MES (PN and CL) BTSCs confirmed a clear separation among the two groups, with the exception of a small number of cell lines that showed a mixed expression profile (Figure 1B and Table S2).

124 To reveal the signaling pathways underlying the differences among MES versus 125 Non-MES BTSCs we then applied a network-based approach based on ARACNe 126 (Algorithm for the Reconstruction of Accurate Cellular Networks) (Basso et al., 2005; 127 Carro et al., 2010), which identifies a list of transcription factors (TFs) with their predicted 128 targets, defined as regulons. The regulon for each TF is constituted by all the genes whose 129 expression data exhibit significant mutual information with that of a given TF and are 130 thus expected to be regulated by that TF (Castro et al., 2016; Fletcher et al., 2013). 131 Enrichment of a relevant gene signature in each of the regulons can point to the TFs acting 132 as master regulators (MRs) of the response or phenotype (Carro et al., 2010; Fletcher et 133 al., 2013). Master regulator analysis (MRA), identified a series of TFs, among which 134 FOSL1, SOX11, OLIG2, CTCF and IRF1 were the top 5 most statistically significant 135 (Benjamini-Hochberg P < 0.0001) (Table S3 and Figure 1C). FOSL1 and IRF1 were 136 significantly upregulated in the MES BTSCs, while SOX11, OLIG2, CTCF were 137 upregulated in the Non-MES BTSCs (Figure S1A and 1D). Gene set enrichment analysis 138 (GSEA) evidenced how the regulons for the top 5 TFs are enriched for genes that are 139 differentially expressed among the two classes (MES and Non-MES) with FOSL1 having 140 the highest enrichment score (Figure 1C and Figure S1B).

We then analyzed the TCGA pan-glioma dataset (Ceccarelli et al., 2016) and observed that *FOSL1* expression is elevated in the IDH-wt glioma molecular subtype (Figure 1E and Table S4) and that high expression levels are associated with worse prognosis in IDH-wt GBM (Figure 1F), thus suggesting that *FOSL1* could represent not only a master regulator of the glioma-intrinsic MES signature, but also a putative key player in MES GBM pathogenesis.

147

148 *NF1* modulates the MES signature and *FOSL1* expression

NF1 alterations and activation of the RAS/MAPK signaling have been previously associated with the MES GBM subtype (Brennan et al., 2013; Verhaak et al., 2010; Wang et al., 2016; Wang et al., 2017). However, whether *NF1* plays a functional role in the regulation of the MES gene signature (MGS) still remains to be established.

153 We initially grouped, according to the previously described subtype-specific gene 154 signatures, a subset of IDH-wt GBM samples of the TCGA dataset for which RNA-seq 155 data were available (n = 152) (see methods for details). By analyzing the frequency of 156 *NF1* alterations (either point mutations or biallelic gene loss) in the different subtypes 157 (Figure 2A), we confirmed a significant enrichment of *NF1* alterations in MES versus 158 Non-MES tumors (Fisher's Exact test P value = 0.03) (Figure 2B). Importantly, we 159 detected higher level of FOSL1 mRNA in the cohort of patient tumors with NF1 160 alterations, both low-grade gliomas (LGGs) and GBMs (Figures 2C and Table S4), with 161 the NF1-altered MES GBMs showing the highest expression levels (Figures 2D and Table 162 S4).

163 To test whether NF1 signaling is directly involved in the regulation of FOSL1 and 164 the MES subtype, we manipulated NF1 expression in patient derived tumorspheres of 165 either the MES or PN subtype (Figure S3A-B). To recapitulate the activity of the full-166 length NF1 protein we transduced the cells with the NF1 GTPase-activating domain 167 (NF1-GRD), spanning the whole predicted Ras GTPase-activating (GAP) domain 168 (McCormick, 1990). NF1-GRD expression in the MES cell line BTSC 233 led to 169 inhibition of RAS activity as confirmed by analysis of pERK expression upon EGF or serum stimulation (Figure S2A-B) as well as by RAS pull down assay (Figure S2C). 170 171 Furthermore, analysis of a RAS-induced oncogenic signature expression by GSEA 172 showed a strong reduction in NF1-GRD expressing cells (NES = -1.7; FDR q-value <173 0.001) (Figure S2D). Most importantly, NF1-GRD expression led to a significant 174 reduction of the MGSs (Wang signature: NES = -1.3; FDR q-value = 0.05; Phillips 175 signature: NES = -1.7; FDR q-value < 0.001) (Figure 2E, left panels). On the contrary, 176 Proneural gene signatures (PNGSs) were upregulated (Wang signature: NES = 1.2; FDR 177 q-value = 0.12; Phillips signature: NES = 1.3; FDR q-value = 0.1) (Figure 2E, right 178 panels). Western blot analysis also revealed a significant decrease of CHI3L1 expression, 179 a well characterized mesenchymal marker, upon NF1-GRD overexpression (Figure 2F).

Mesenchymal glioblastoma cells are able to differentiate into osteocytes, a feature they share with mesenchymal stem cells (Ricci-Vitiani et al., 2008; Tso et al., 2006). Consistent with the loss of the MGS, the ability to differentiate into osteocytes was lost in the BTSC 233 MES cells transduced with the NF1-GRD, as documented by Alizarin Red staining (Figure 2G).

185To further confirm whether *NF1* deletion could be sufficient to induce changes in186the MGS, we then knocked down *NF1* in the NF1-expressing PN cell line BTSC 3021

(Figure 2H) and performed microarray gene expression analysis followed by GSEA. Both
Wang and Phillips MGSs were enriched upon NF1 silencing (Wang: NES = 1.61; FDR
q-value = 0.005; Phillips: NES = 1.9; FDR q-value < 0.001) (Figure 2I). The PNGSs
instead were not significantly lost (data not shown).

- 191 Taken together, our data indicate that NF1 modulation is able to alter the MGS 192 expression in GBM. NF1-led gene expression changes might be driven by an effect on 193 MGS master regulators. Alternatively, other TFs might be involved. We therefore 194 analyzed the expression of FOSL1 and other previously described mesenchymal TFs 195 (Bhat et al., 2011; Carro et al., 2010) upon NF1-GRD overexpression or NF1 loss in two 196 independent MES (BTSC 233 and BTSC 232) or PN (BTSC 3021 and BTSC 3047) cell 197 lines. Interestingly, only CEBPB and FOSL1 were consistently downregulated upon NF1-198 GRD expression (Figure 2J and S3C) and upregulated following NF1 knockdown 199 (Figures 2K and S3D). Moreover, a FOSL1 targets signature was enriched in the NF1 200 altered versus NF1 wt GBM samples of the TCGA dataset as well as in the BTSC 3021 201 shNF1 versus shCtrl (*NF1* altered: NES = 1.38; FDR q-value = 0.16; shNF1: NES = 1.9; 202 FDR q-value < 0.001) (Figure S3E, top and middle panels). Conversely, *FOSL1* targets 203 were downregulated upon NF1-GRD (NF1-GRD: NES = -1.38; FDR q-value = 0.037) 204 (Figure S3E, bottom panel). These data were further confirmed by the analysis of the 205 expression of some FOSL1 targets (ITGA3, PLAU, ITGA5, TNC and SERPINE1): we 206 observed that ITGA3 and SERPINE1 were consistently either downregulated upon NF1-207 GRD overexpression (Figure S3F, NF1-GRD in BTSC 233 and BTSC 232) or 208 upregulated upon NF1 knockdown (Figure S3G, shNF1 in BTSC 3021 and BTSC 3047). 209 Overall these evidences suggest that NF1 is directly involved in the regulation of
- 210 the MGS, possibly through the modulation of *FOSL1* expression.
- 211

212 Fosl1 deletion induces a shift from a MES to a PN gene signature

213 To further explore the NF1-FOSL1 axis in MES GBM we used a combination of 214 the RCAS-Tva system with the CRISPR/Cas9 technology, recently developed in our 215 laboratory (Oldrini et al., 2018) to induce Nfl loss or Kras mutation. Mouse neural stem cells (NSCs) from hGFAP-Tva; hGFAP-Cre; Trp53^{lox}; ROSA26-LSL-Cas9 pups were 216 217 isolated and infected with viruses produced by DF1 packaging cells transduced with 218 RCAS vectors targeting the expression of Nfl through shRNA and sgRNA (shNfl and sgNf1) or overexpressing a mutant form of Kras (Kras^{G12V}). Loss of NF1 expression was 219 220 confirmed by western blot and FRA-1 was upregulated in the two models of Nfl loss

221 compared to parental cells, and further upregulated in cells infected with $Kras^{G12V}$ (Figure 222 3A). Consistent with activation of the Ras signaling, as result of both *Nf1* loss and *Kras* 223 mutation, the MEK/ERK pathway was more active in infected cells compared to parental 224 cells (Figure 3A). Higher levels of activation of the MEK/ERK pathway were associated 225 with the induction of mesenchymal genes such as *Plau*, *Plaur*, *Timp1* and *Cd44* (Figure 226 3B). These data indicated that *Kras*^{G12V}–transduced cells are a suitable model to 227 functionally study the role of *Fosl1* in MES GBM.

Taking advantage of the Cas9 expression in the generated cell p53-null $Kras^{G12V}$ NSCs model, *Fosl1* expression was knocked out through sgRNAs. Efficient downregulation of FRA-1 was achieved with 2 different sgRNAs (Figure 3C). Cells transduced with sg*Fosl1*_1 and sg*Fosl1*_3 were then subjected to further studies.

232 As suggested by the data presented here on the human BTSCs datasets (Figures 233 1C-D and 2K), FOSL1 appears to be a key regulator the MES subtype. Consistently, RNA-seq analysis followed by GSEA of p53-null Kras^{G12V} sgFosl1 1 versus sgCtrl 234 235 revealed a significant loss of Wang and Phillips MGSs (Wang: NES = -1.85; FDR q-value 236 < 0.001; Phillips: NES = -1.91; FDR q-value < 0.001) (Figure 3D, left panels). 237 Oppositely, Wang and Phillips PNGSs were increased in sgFosl1 1 cells (Wang: NES = 238 1.42; FDR q-value = 0.029; Phillips: NES = 2.10; FDR q-value < 0.001) (Figure 3D, right 239 panels). These findings were validated by qRT-PCR with a significant decrease in expression of a panel of MES genes (Plau, Itga7, Timp1, Plaur, Fn1, Cyr61, Actn1, 240 241 S100a4, Vim, Cd44) (Figure 3E) and increased expression of PN genes (Olig2, Ncam1, Bcan, Lgr5) in the Fosl1 knock-out (KO) Kras^{G12V} NSCs (Figure 3F). 242

243

244 Fosl1 deletion reduces stemness and tumor growth

Ras activating mutations have been widely used to study gliomagenesis, in combination with other alterations as Akt mutation (Holland et al., 2000), loss of Ink4a/Arf (Uhrbom et al., 2002) or p53 (Friedmann-Morvinski et al., 2012; Koschmann et al., 2016; Muñoz et al., 2013). Thus, we then explored the possibility that *Fosl1* could modulate the tumorigenic potential of the p53-null *Kras* mutant cells.

Cell viability was significantly decreased in *Fosl1* KO cell lines, as compared to sgCtrl (Figure 4A). Concomitantly, we observed a significant decreased percentage of cells in S-phase (mean values: sgCtrl = 42.6%; sg*Fosl1_*1 = 21.6%, P \leq 0.001; sg*Fosl1_*3 = 20.4%, P = 0.003) and an increase in percentage of cells in G2/M (mean values: sgCtrl = 11.7%, sg*Fosl1_1* = 28.4%, P \leq 0.001; sg*Fosl1_3* = 23.4%, P = 0.012) (Figure 4B).

255 Another aspect that contributes to GBM aggressiveness is its heterogeneity, 256 attributable in part to the presence of glioma stem cells. By using limiting dilution assays, 257 we found that *Fosl1* is required for the maintenance of stem cell capacity (Figure 4C). 258 Moreover, RNA-seq analysis showed that sgFosl1 1 cells downregulated the expression 259 of stem genes (Elf4, Klf4, Itgb1, Nes, Sall4, L1cam, Melk, Cd44, Myc, Fut4, Cxcr4, 260 *Prom1*) while upregulating the expression of lineage-specific genes: neuronal (*Map2*, 261 Ncam1, Tubb3, Slc1a2, Rbfox3, Dcx), astrocytic (Aldh111, Gfap, S100b, Slc1a3) and 262 oligodendrocytic (Olig2, Sox10, Cnp, Mbp, Cspg4) (Figure 4D). The different expression 263 of some of the stem/differentiation markers was confirmed also by immunofluorescence 264 analysis. While Fosl1 KO cells presented low expression of the stem cell marker CD44, 265 differentiation markers as GFAP and OLIG2 were significantly higher when compared to 266 sgCtrl cells (Figure 4E, Figure S4).

We then sought to test whether: i) p53-null Kras^{G12V} NSCs were tumorigenic and 267 ii) Fosl1 played any role in their tumorigenic potential. Intracranial injections of p53-null 268 *Kras^{G12V}* NSCs in *nu/nu* mice led to the development of high-grade tumors with a median 269 270 survival of 37 days in control cells (n=9). However, the sgFosl1 1 injected mice (n=6) 271 had a significant increase in median survival (54.5 days, Log-rank P = 0.0263) (Figure 272 4F). Consistent with what we detected in vitro (Figure 3D-F) we observed a switch from 273 a MGS to a PNGS in the tumors (Figure 4G-I). By western blot and immunohistochemical 274 analysis, we observed a reduction on expression of MES markers (VIM, CD44 and 275 S100A4) as compared to sgCtrl tumors (Figure 4G-H), while the PN marker OLIG2 was 276 only found expressed in sgFosl1 tumors (Figure 4G). Similarly, when we compared 277 mRNA expression of a sgCtrl tumor with high FRA-1 expression (T4, Figure 4G) with 278 sgFosl1 tumors with no detectable FRA-1 expression by western blot (T3 and T4, Figure 279 4G), we found downregulated expression of MES markers and upregulated expression of 280 PN markers in the sgFosl1 tumors (Figure 4I-J).

Altogether, our data support the conclusion that, besides controlling cell proliferation, *Fosl1* plays a critical role in the maintenance of the stem cell properties and tumorigenicity of p53-null *Kras* mutant NSCs.

- 284
- 285 Fosl1 amplifies MES gene expression

To further assess the role of *Fosl1* as a key player in the control of the MGS, we
used a mouse model of inducible *Fosl1* overexpression containing the alleles *Kras^{LSLG12V}*; *Trp53^{lox}*; *ROSA26^{LSLrtTA-IRES-EGFP}*; *Col1a1^{TetO-Fosl1}* (here referred as *Fosl1^{tetON}*). Similar to

the loss-of-function approach here used, this allelic combination allows the expression of *Kras*^{G12V} and deletion of *p53* after Cre recombination. Moreover, the expression of the reverse tetracycline transactivator (rtTA) allows, upon induction with doxycycline (Dox), the ectopic expression of *Fosl1* (Flag tagged), under the control of the *Col1a1* locus and a tetracycline-responsive element (TRE or Tet-O) (Belteki et al., 2005; Hasenfuss et al., 2014).

NSCs derived from Fosl1^{WT} and Fosl1^{tetON} mice were infected in vitro with a 295 296 lentiviral vector expressing the Cre recombinase and efficient infection was confirmed by 297 fluorescence microscopy, as the cells expressing the rtTA should express GFP (data not 298 shown). FRA-1 overexpression, as well as Flag-tag expression was then tested by western 299 blot after 72h of Dox induction (Figure 5A). When *Fosl1^{tetON}* NSCs were analyzed by qRT-PCR for the expression of MES/PN markers, a significant upregulation of most MES 300 301 genes and downregulation of PN genes was found in the cells overexpressing Fosl1 upon 302 Dox induction (Figure 5B-C), the inverse image of our findings with Fosl1 knock-out 303 cells.

304 In order to investigate if the MES phenotype induced with *Fosl1* overexpression would have any effect *in vivo*, p53-null *Kras^{G12V} Fosl1^{tetON}* NSCs were intracranially 305 306 injected into syngeneic C57BL/6J wildtype mice. Injected mice were randomized and 307 subjected to Dox diet (food pellets and drinking water) or kept as controls with regular 308 food and drinking water with 1% sucrose. No differences in mice survival were observed 309 (Figure S5B). However, tumors developed from *Fosl1* overexpressing mice (+Dox) were 310 larger (Figure 5D), more infiltrative and with a more aggressive appearance than controls 311 (-Dox), that mostly grew as superficial tumor masses, even if both -Dox and +Dox 312 tumors seem to proliferate similarly (Figure S5C).

313 Tumorspheres were derived from -Dox and +Dox tumor-bearing mice and Fosl1 314 expression was manipulated *in vitro* through addition or withdrawal of Dox from the 315 culture medium. In the case of tumorspheres derived from a –Dox tumor, when Dox was 316 added for 19 days, high levels of FRA-1 expression were detected by western blot (Figure 317 5E). At the mRNA level, Dox treatment also greatly increased *Fosl1* expression, as well 318 as some of the MES genes (Figure 5F), while the expression of PN genes was 319 downregulated (Figure 5G). Conversely, when Dox was removed from +Dox derived 320 tumorspheres for 19 days, the expression of FRA-1 decreased (Figure 5H-I), along with 321 the expression of MES genes (Figure 5I), while PN genes were upregulated (Figure 5J). 322 These results confirm the essential role of *Fosl1* in the regulation of the MES gene

signature in p53-null *Kras^{G12V}* tumor cells and the plasticity between the PN and MES
subtypes.

325

326 *FOSL1* controls growth, stemness and MES gene expression in patient-derived 327 tumor cells

328 To prove the relevance of our findings in the context of human tumors, we 329 analyzed BTSC lines characterized as Non-MES (BTSC 268 and 409) or MES (BTSC 330 349 and 380) (Figure 1A). By western blot, we found that MES BTSC 380 did not express 331 NF1 while BTSC 349 showed a different pattern of NF1 expression compared to the Non-332 MES lines BTSC 268 and 409 (intact NF1), that might be due to a NF1 point mutation. 333 Consistent with the observed upon NF1 silencing either in human BTSCs (Figure 2I) or 334 mouse NSCs (Figure 3A), both MES cell lines expressed high levels of FRA-1 and 335 activation of the MEK/ERK pathway (Figure 6A).

336 To study the role of FOSL1 in the context of human BTSCs, its expression was 337 silenced in the MES BTSC 349, the cell line with higher FRA-1 expression, using a Dox 338 inducible shRNA. We confirmed by western blot FRA-1 downregulation after 3 days of 339 Dox treatment (Figure 6B). Similar to what was observed in the mouse cells, FOSL1 340 silencing in MES BTSC 349 resulted in reduced cell growth (Figure 6C) with a significant 341 reduction of the percentage of BrdU positive cells, compared to Dox-untreated cells 342 (Figure S6A). FOSL1 silencing through Dox treatment also decreased stem cell sphere 343 forming capacity of MES BTSC 349 (Figure 6D). Moreover, FOSL1 silencing resulted 344 also in the significant downregulation of the MES genes (Figure 6E), while no major 345 differences in the expression of PN genes was observed (Figure S6B).

346 Lastly, we tested whether FRA-1 modulates the MGS via direct target regulation. 347 To this end, we first identified high-confidence FOSL1/FRA-1 binding sites in chromatin 348 immunoprecipitation-seq (ChIP-seq) generated in non-mesenchymal cancer cells (see 349 methods) and then we determined the counts per million reads (CPM) of the enhancer 350 histone mark H3K27Ac in a set of MES and non-MES BTSCs (Mack et al., 2019). 351 Differential enrichment analysis by DeSeq2 revealed 9262 regions statistically significant 352 for H3K27Ac at FOSL1/FRA-1 binding sites in either MES or non-MES BTSCs (Figure 353 6F). Gene set enrichment analysis revealed that a significant fraction of H3K27Ac-354 decorated FOSL1/FRA-1 binding sites was enriched in MES BTSCs and PCA further 355 revealed that H3K27Ac-decorated sites in MES BTSCs clustered closer to FOSL1/FRA-356 1 direct binding to chromatin when compared to non-MES BTSCs (Figure 6G). Next, we

357 compared H3K27Ac distribution over FOSL1/FRA-1 binding sites to that of the Non-358 MES master regulator OLIG2 (Figure 1C). This analysis showed that the 9262 359 FOSL1/FRA-1 binding sites are systematically decorated with H3K27Ac in MES BTSCs, 360 whereas only 3423 out of 9262 sites are acetylated to a similar extent in non-MES BTSCs. 361 Importantly, the inverse trend was observed for H3K27Ac at OLIG2 binding sites (Figure 362 6H). Validation in an independent MES BTSC line (BTSC 349) by ChIP-qPCR 363 confirmed FRA-1 binding at promoters of some MES genes including PLAU, TNC, 364 ITGA5 and CD44 (Figure 6J).

Altogether, our data support that *FOSL1*/FRA-1 regulates MES gene expression and aggressiveness in human gliomas via direct transcriptional regulation, downstream of NF1.

368

369 **Discussion**

370 The most broadly accepted transcriptional classification of GBM was originally 371 based on gene expression profiles of bulk tumors (Verhaak et al., 2010), which did not 372 discriminate the contribution of tumor cells and TME to the transcriptional signatures. It 373 is now becoming evident that both cell-intrinsic and extrinsic cues can contribute to the 374 specification of the MES subtype (Bhat et al., 2013; Neftel et al., 2019; Wang et al., 2017). 375 Bhat and colleagues had shown that while some of the MES GBMs maintained the 376 mesenchymal characteristics when expanded in vitro as BTSCs, some others lost the 377 MGS after few passages while exhibiting a higher PNGS (Bhat et al., 2013). These data, 378 together with the evidence that xenografts into immunocompromised mice of BTSCs 379 derived from MES GBMs were also unable to fully restore the MES phenotype, suggested 380 that the presence of an intact TME potentially contributed to the maintenance of a MGS, 381 either by directly influencing a cell-intrinsic MGS or by expression of the TME-specific 382 signature. Recently, the transcriptional GBM subtypes were redefined based on the 383 expression of glioma-intrinsic genes, thus excluding the genes expressed by cells of the 384 TME (Wang et al., 2017). Our master regulator analysis on the BTSCs points to the AP-385 1 family member FOSL1 as one of the top transcription factors contributing to the cell-386 intrinsic MGS. Previous tumor bulk analysis identified a related AP-1 family member 387 FOSL2, together with CEBPB, STAT3 and TAZ, as important regulators of the MES GBM 388 subtype (Bhat et al., 2011; Carro et al., 2010). While FOSL1 was also listed as a putative 389 MES master regulator (Carro et al., 2010), its function and mechanism of action have not 390 been further characterized since then. Our experimental data show that FOSL1 is a key

regulator of GBM subtype plasticity and MES transition, and define the molecularmechanism through which *FOSL1* is regulated.

393 Although consistently defined, GBM subtypes do not represent static entities. The 394 plasticity between subtypes happens at several levels. Besides the referred MES-to-PN 395 change in cultured GSCs compared to the parental tumor (Bhat et al., 2013), a PN-to-396 MES shift often occurs upon treatment and recurrence. Several independent studies 397 comparing matched pairs of primary and recurrent tumors demonstrated a tendency to 398 shift towards a MES phenotype, associated with a worse patient survival, likely as a result 399 of treatment-induced changes in the tumor and/or the microenvironment (Phillips et al., 400 2006; Wang et al., 2016; Wang et al., 2017). Moreover, distinct subtypes/cellular states, 401 can coexist within the same tumor (Neftel et al., 2019; Patel et al., 2014; Sottoriva et al., 402 2013; Wang et al., 2019) and targeting these multiple cellular components could result in 403 more effective treatments (Wang et al., 2019).

404 PN-to-MES transition is often considered an EMT-like phenomenon, associated 405 with tumor progression (Fedele et al., 2019). The role of FOSL1 in EMT has been studied 406 in other tumor types. In breast cancer cells FOSL1 expression correlates with 407 mesenchymal features and drives cancer stem cells (Tam et al., 2013) and the regulation 408 of EMT seems to happen through the direct binding of FRA-1 to promoters of EMT genes 409 such as Tgfb1, Zeb1 and Zeb2 (Bakiri et al., 2015). In colorectal cancer cells, FOSL1 was 410 also shown to promote cancer aggressiveness through EMT by direct transcription 411 regulation of EMT-related genes (Diesch et al., 2014; Liu et al., 2015).

412 It is well established that *NF1* inactivation is a major genetic event associated with 413 the MES subtype (Verhaak et al., 2010; Wang et al., 2017). However, this is probably a 414 late event in MES gliomagenesis, as all tumors possibly arise from a PN precursor and 415 just later in disease progression acquire NF1 alterations that are directly associated with 416 a transition to a MES subtype (Ozawa et al., 2014). Moreover, NF1 deficiency has been 417 recently linked to macrophage/microglia infiltration in the MES subtype (Wang et al., 418 2017). The fact that the enriched macrophage/microglia microenvironment is also able to 419 modulate a MES phenotype suggests that there might be a two-way interaction between 420 tumor cells and TME. The mechanisms of NF1-regulated chemotaxis and whether this 421 relationship between the TME and MGS in GBM is causal remain elusive.

Here we provide evidence that manipulation of *NF1* expression levels in patientderived BTSCs has a direct consequence on the tumor-intrinsic MGS activation and that such activation, can at least in part be mediated by the modulation of *FOSL1*. Among the

previously validated MRs, only *CEBPB* appears also to be finely modulated by *NF1*inactivation. This suggests that among the TFs previously characterized (such as *FOSL2*, *STAT3*, *BHLHB2* and *RUNX1*), *FOSL1* and *CEBPB* might play a specific role in the *NF1*mediated MES transition that occurs in glioma cells with limited or possibly absent effect
by the TME. However, whether *FOSL1* contributes also to the putative cross-talk between
the TME and the cell-intrinsic MGS, will still have to be established.

431 Furthermore we show that *FOSL1* is a crucial player in glioma pathogenesis, 432 particularly in a MAPK-driven MES GBM context. Our findings broaden its previously 433 described role in KRAS-driven epithelial tumors, such as lung and pancreatic ductal 434 adenocarcinoma (Vallejo et al., 2017). NF1 inactivation results in Ras activation, which 435 stimulates downstream pathways as MAPK and PI3K/Akt /mTOR. RAS/MEK/ERK 436 activation in turn regulates FOSL1 mRNA expression and FRA-1 protein stability 437 (Casalino et al., 2003; Verde et al., 2007). FRA-1 can then directly bind and activate some 438 of the MES genes, while possibly binding its own promoter to activate its own expression 439 (Diesch et al., 2014; Lau et al., 2016). This generates a feedback loop that induces MGS, 440 increases proliferation and stemness, sustaining tumor growth. FRA-1 requires, for its 441 transcriptional activity, heterodimerization with the AP-1 transcription factors JUN, 442 JUNB or JUND (Eferl and Wagner, 2003). Which of the JUN family members participate 443 in the MES gene regulation and whether FRA-1 activates MES gene expression and 444 simultaneously represses PN genes, requires further investigation.

In conclusion, *FOSL1* is a master regulator of the MES subtype of GBM, significantly contributing to its stem cell features, which could open new therapeutic options. Although *FOSL1* pharmacological inhibition is difficult to achieve due to the lack of specific inhibitors, a gene therapy approach targeting *FOSL1* expression through CRISPR, for instance, could constitute an attractive alternative to treat MES GBM patients.

451

452 Acknowledgements

We would like to thank Álvaro Ucero for his input on the project and Flora A. Díaz for her technical support. We are grateful to Francisco X. Real and Scott Lowe for critical input on the manuscript. We thank Pamela Franco for experimental support and discussion. This work was supported by a grant from the Marie Curie International reintegration Grants (MC-IRG), project nr. 268303 (to M.S.C.) and by grants from the

458 ISCIII, project PI13/01028, cofounded by the European Regional Development Fund459 (ERDF), and from the Seve Ballesteros Foundation (to M.S.).

460

461 Author Contributions

462 C.M designed and performed experiments, analyzed data and wrote the 463 manuscript. T.U., P.K., A.I. and E.K. performed experiments. G.G. analyzed data and 464 interpreted experiments. O.S. provided tumor samples. S.N. provided cell lines. L.B. and 465 E.F.W. provided reagents, contributed to experimental design and interpreted 466 experiments. M.S.C and M.S. conceived the project, designed and interpreted 467 experiments and wrote the manuscript.

468

469 **Declaration of interests**

- 470 The authors declare no competing interests.
- 471

472 Material and Methods

473 Generation of the BTSCs dataset and Master regulator analysis (MRA)

474 The brain tumor stem cell lines (BTSCs) dataset was assembled with new and previously 475 generated transcriptomic data: 24 Illumina HumanHT-12v4 expression BeadChip 476 microarrays newly generated at Freiburg University (GSE137310, this study); 44 RNA-477 seq samples (Illumina HiSeq 2500) from GSE119834 (Mack et al., 2019), 30 Affymetrix 478 Human Genome U219 microarrays from GSE67089 (Mao et al., 2013) and 17 Affymetrix 479 HG-U133 Plus 2.0 microarrays from GSE8049 (Günther et al., 2008). For the previously 480 published data, at exception of the GSE119834, for which pre-processed data were used, 481 raw data were downloaded from the GEO repository 482 (https://www.ncbi.nlm.nih.gov/geo/) and subsequently the 'affy' package (R 483 programming language) was used for robust multi-array average normalization followed 484 by quantile normalization. For genes with several probe sets, the median of all probes had 485 been chosen and only common genes among all the datasets (n = 14821) were used for 486 further analysis. To avoid issues with the use of different transcriptomic platforms each 487 dataset was then scaled (mean = 0, sd = 1) before assembling the combined final dataset. 488 Transcriptional subtypes were obtained using the 'ssgsea.GBM.classification' R package 489 (Wang et al., 2017), through the SubtypeME tool of the GlioVis web portal

490 (http://gliovis.bioinfo.cnio.es) (Bowman et al., 2017). Differential gene expression (MES
491 vs Non-MES BTSCs) was performed using the 'limma' R package.

492 The master regulator analysis was performed using the 'RTN' R package (Castro 493 et al., 2016). Normalized BTSC expression data were used as input to build a 494 transcriptional network (TN) for 785 TFs present in the dataset. TF annotations were 495 obtained from Gene Ontology (GO:0003700). P values for network edges were computed 496 from a pooled null distribution using 1000 permutations. Edges with an adjusted-P value 497 < 0.05 were kept for data processing inequality (DPI) filtering. In the TN, each target can 498 be connected to multiple TFs and regulation can occur as a result of both direct and 499 indirect interactions. DPI-filtering removes the weakest interaction in any triangle of two 500 TFs and a target gene, therefore preserving the dominant TF-target pairs and resulting in 501 a filtered TN that highlights the most significant interactions (Fletcher et al., 2013). Post-502 DPI filtering, the MRA computes the overlap between the transcriptional regulatory 503 unities (regulons) and the input signature genes using the hypergeometric distribution 504 (with multiple hypothesis testing corrections). To identify master regulators, the 505 differential gene expression between MES and Non-MES was used as a phenotype.

506

507 TCGA pan-glioma data analysis

RSEM normalized RNA-seq data for the TCGA GBMLGG dataset were downloaded from the Broad Institute Firebrowse (<u>http://gdac.broadinstitute.org</u>). *NF1* copy number alterations and point mutations were obtained at the cBioPortal (<u>https://www.cbioportal.org</u>). Transcriptional subtypes were inferred using the 'ssgsea.GBM.classification' R package as indicated above. Glioma molecular subtypes information was downloaded from the GlioVis web portal (http://gliovis.bioinfo.cnio.es) (Bowman et al., 2017). Survival analysis was performed using the 'survival' R package.

516 Gene Expression Array and gene set enrichment analysis (GSEA)

517 For gene expression profiling of the BTSC lines of the Freiburg dataset, total RNA 518 was prepared using the RNeasy kit (Qiagen #74104) or the AllPrep DNA/RNA/Protein 519 mini kit (Qiagen #80004) and quantified using 2100 Bioanalyzer (Agilent). One-and-a-520 half μg of total RNA for each sample was sent to the genomic facility of the German 521 Cancer Research Center (DKFZ) in Heidelberg (Germany) where hybridization and data 522 normalization were performed. Hybridization was carried out on Illumina HumanHT-

523 12v4 expression BeadChip. Gene set enrichment analysis was performed using the GSEA
524 software (http://www.broadinstitute.org/gsea/index.jsp).

525

526 ChIP-seq analysis

527 We downloaded FOSL1 ChIP-seq profiling from ENCODE tracks ENCFF0000ZR and 528 ENCFF0000ZQ. OLIG2 binding sites and ChIP-seq profiles were downloaded from 529 GEO: GSM1306365 MGG8TPC.OLIG2r1c and GSM1306367 MGG8TPC.OLIG2r2. 530 H3K27Ac data were downloaded from GSE119755 (Mack et al., 2019) for 531 GSM3382291 GSC17, GSM3382343 GSC40, GSM3382319 GSC3, 532 GSM3382321 GSC30, GSM3382341 GSC4, GSM3382277 GSC10. Scatter plots were 533 generated with Seqmonk v1.45 using FOSL1 binding sites in MES-BTSCs using a 534 Kolmorogov-Smirnov test with a sample size of 297 when constructing the control 535 distributions and filtering by maximum P value of 0.05 (multiple testing correction 536 applied). Minimum absolute z-score was 0.5. A custom regression was calculated. 537 Quantitation was Read Count Quantitation using all reads correcting for total count only 538 in probes to largest store log transformed duplicates ignored. Heatmaps were generated 539 using ChaSE, using either FOSL1 or OLIG2 binding sites with $\pm 10,000$ bp.

540

541 Mouse strains and husbandry

542 *GFAP-tv-a; hGFAP-Cre; Rosa26-LSL-Cas9* mice were previously described 543 (Oldrini et al., 2018). *Kras^{LSLG12V}; Trp53^{lox}; Rosa26^{LSLrtTA-IRES-EGFP}; Col1a1^{TetO-Fosl1}* 544 mouse strain corresponds to the MGI Allele References 3582830, 1931011, 3583817 and 545 5585716, respectively. Immunodeficient *nu/nu* mice (MGI: 1856108) were obtained at 546 the Spanish National Cancer Research Centre Animal Facility.

547 Mice were housed in the specific pathogen-free animal house of the Spanish 548 National Cancer Research Centre under conditions in accordance with the 549 recommendations of the Federation of European Laboratory Animal Science 550 Associations (FELASA). All animal experiments were approved by the Ethical 551 Committee (CEIyBA) and performed in accordance with the guidelines stated in the 552 International Guiding Principles for Biomedical Research Involving Animals, developed 553 by the Council for International Organizations of Medical Sciences (CIOMS).

554

555 Cell lines and cell culture

556 Mouse neural stem cells (NSCs) were derived from the whole brain of newborn 557 mice of Gtv-a; hGFAP-Cre; LSL-Cas9; Trp53lox (referred as p53-null NSCs) and Kras^{LSLG12V}; Trp53^{lox}; Rosa26^{LSLrtTA-IRES-EGFP}; Collal^{TetO-Fosl1} (referred as Fosl1^{TetON} 558 559 NSCs). Tumorsphere lines were derived from tumors of C57BL/6J injected with Fosl1^{TetON} NSCs, when mice were sacrificed after showing symptoms of brain tumor 560 disease. For the derivation of mouse NSCs and tumorspheres, tissue was enzymatically 561 562 digested with 5 mL of papain digestion solution (0.94 mg/mL papain (Worthington 563 #LS003119), 0.48 mM EDTA, 0.18 mg/mL N-acetyl-L-cysteine (Sigma-Aldrich 564 #A9165) in Earl's Balanced Salt Solution (Gibco #14155-08)) and incubated at 37°C for 565 8 min. After digestion, the enzyme was inactivated by the addition of 2 mL of 0.71 mg/mL 566 ovomucoid (Worthington #LS003087) and 0.06 mg/mL DNaseI (Roche #10104159001) 567 diluted in Mouse NeuroCult basal medium (Stem Cell Technologies #05700) without 568 growth factors. Cell suspension was centrifuged at a low speed and then passed through a 40 µm mesh filter to remove undigested tissue, washed first with PBS and then with 569 570 ACK lysing buffer (Gibco #A1049201) to remove red blood cells. NSCs and 571 tumorspheres were grown in Mouse NeuroCult basal medium, supplemented with 572 Proliferation supplement (Stem Cell Technologies #05701), 20 ng/mL recombinant 573 human EGF (Gibco #PHG0313), 10 ng/mL basic-FGF (Millipore #GF003-AF), 2 µg/mL 574 Heparin (Stem Cell Technologies #07980) and L-glutamine (2mM, Hyclone 575 #SH3003401). Spheres were dissociated with Accumax (ThermoFisher Scientific #00-576 4666-56) and re-plated every 4-5 days.

Patient-derived glioblastoma stem cells (BTSCs) were prepared from tumor
specimens under IRB-approved guidelines as described before (Fedele et al., 2017).
BTSCs were grown as neurospheres in Neurobasal medium (Gibco #10888022)
containing B27 supplement (Gibco #12587010), N2 supplement (Gibco #17502048), bFGF (20 ng/mL), EGF (20 ng/mL), LIF (10 ng/mL, CellGS #GFH200-20), 2 µg/mL
Heparin and L-glutamine (2mM). JX6 were kindly provided by Y. Gillespie (UAB,
Birmingham).

584

585 Vectors, virus production and infection

586 Flag-tagged NF1-GRD (aminoacids 1131-1534) was amplified by PCR from 587 human cortical tissue (epilepsy patient) and first cloned in the pDRIVE vector. Primers 588 are listed in Table S5. The NF1-GRD sequence was then excised by restriction digestion 589 using PmeI and SpeI enzymes and subcloned in the modified pCHMWS lentiviral vector

590 (kind gift from V. Baekelandt, University of Leuven, Belgium) sites by removing the 591 fLUC region. The correct sequence was verified by sequencing. For NF1 silencing, NF1 592 short hairpin from pLKO (Sigma, TRCN0000238778) vector was subcloned in pGIPZ 593 lentiviral vector (Open Biosystems). The corresponding short hairpin sequence was 594 synthetized (GATC) and amplified by PCR using XhoI and EcoRI sites containing 595 primers. The PCR product was digested using XhoI and EcoRI and subcloned into the 596 pGIPZ vector previously digested with XhoI and PmeI following by digestion with 597 EcoRI. The two vector fragments were ligated with NF1 short hairpin fragment. The 598 correct insertion and sequence was validated by sequencing. In addition, experiments 599 were performed using shNF1-pGIPZ clone V2LHS 76027 (clone 4) and V2LHS 260806 600 (clone 5).

601 RCAS viruses (RCAS-sh*Nf1*, RCAS-sg*Nf1* and RCAS-*Kras*^{G12V}) used for 602 infection of p53-null NSCs were obtained from previously transfected DF1 chicken 603 fibroblasts (ATCC #CRL-12203) using FuGENE 6 Transfection reagent (Promega 604 #E2691), according to manufacturer's protocol. DF1 cells were grown at 39°C in DMEM 605 containing GlutaMAXTM (Gibco #31966-021) and 10% FBS (Sigma-Aldrich #F7524).

606 The pKLV-U6gRNA-PGKpuro2ABFP was a gift from Dr. Kosuke Yusa 607 (Wellcome Sanger Insitute) (Addgene plasmid #50946). For cloning of single gRNAs, 608 oligonucleotides containing the BbsI site and the specific gRNA sequences were 609 annealed, phosphorylated and ligated into the pKLV-U6gRNA(BbsI)-PGKpuro2ABFP 610 previously digested with BbsI. Single gRNAs to target Fosl1 were designed with Guide 611 Scan (<u>http://www.guidescan.com/</u>) and the sequences cloned were sgFosl1 1: 612 TACCGAGACTACGGGGAACC; sgFosl1 2: CCTAGGGCTCGTATGACTCC; 613 sgFosl1 3: ACCGTACGGGCTGCCAGCCC. These vectors and a non-targeting sgRNA 614 control were used to transduce p53-null Kras^{G12V} NSCs.

615 The pLVX-Cre and respective control vector were kindly provided by Dr. Maria 616 Blasco (CNIO) and used to transduce *Fosl1^{TetON}* NSCs; pLKO.1-TET-sh*FOSL1* and 617 respective control vector were a gift from Dr. Silve Vicent (CIMA, Navarra University).

618 Gp2-293 packaging cell line (Clontech #631458) was grown in DMEM (Sigma-619 Aldrich #D5796) with 10% FBS. Lentiviruses generated in this cell line were produced 620 using calcium-phosphate precipitate transfection and co-transfected with second-621 generation packaging vectors (pMD2G and psPAX2). High-titer virus was collected at 622 36 and 60 h following transfection.

All cells were infected with lenti- or retroviruses by four cycles of spin infection (200 × g for 2 h), in presence of 8 μ g/mL polybrene (Sigma-Aldrich #H9268). Transduced cells were selected after 48 h from the last infection with 1 μ g/mL Puromycin (Sigma-Aldrich #P8833).

627

628 Generation of murine gliomas

629 p53-null *Kras*^{G12V} NSCs (5×10^5 cells) were injected intracranially into 4 to 5 630 weeks-old immunodeficient *nu/nu* mice.

 $Fosl1^{TetON}$ NSCs (5×10⁵ cells) were intracranially injected into 4 to 5 weeks-old wildtype C57Bl/6J mice that were fed *ad libitum* with 2 g/kg doxycycline-containing pellets. Due to the limited penetration of the blood brain barrier and to insure enough Dox was reaching the brain, 2 mg/mL Dox (PanReac AppliChem #A29510025) was also added to drinking water with 1% sucrose (Sigma-Aldrich #S0389) (Annibali et al., 2014; Mansuy and Bujard, 2000). Control mice were kept with regular food and 1% sucrose drinking water.

Mice were anaesthetized with 4% isofluorane and then injected with a stereotactic apparatus (Stoelting) as previously described (Hambardzumyan et al., 2009). After intracranial injection, all mice were routinely checked and sacrificed when developed symptoms of disease (lethargy, poor grooming, weight loss and macrocephaly).

642

643 Immunohistochemistry

Tissue samples were fixed in 10% formalin, paraffin-embedded and cut in 3 μm
sections, which were mounted in Superfrost Plus microscope slides (Thermo Scientific
#J1810AMNZ) and dried. Tissues were deparaffinized in xylene and re-hydrated through
graded concentrations of ethanol in water, ending in a final rinse in water.

648 For histopathological analysis, sections were stained with hematoxylin and eosin649 (H&E).

For immunohistochemistry, deparaffinized sections underwent heat-induced antigen retrieval, endogenous peroxidase activity was blocked with 3% hydrogen peroxide (Sigma-Aldrich #H1009) for 15 min and slides were then incubated in blocking solution (2.5% BSA (Sigma-Aldrich #A7906) and 10% Goat serum (Sigma-Aldrich #G9023), diluted in PBS) for at least 1 h. Incubations with anti-FRA-1 (Santa Cruz #sc-183, 1:100) and anti-CD44 (BD Biosciences #550538, 1:100) were carried out overnight at 4°C. Slides were then incubated with secondary anti-rabbit (Vector #BA-1000) or anti-

rat (Vector #BA-9400) for 1 h at RT and with AB (avidin and biotinylated peroxidase) solution (Vectastain Elite ABC HRP Kit, Vector, PK-6100) for 30 min. Slides were developed by incubation with peroxidase substrate DAB (Vector SK-4100) until desired stain intensity. Finally, slides were counterstained with hematoxylin, cleared and mounted with a permanent mounting medium.

Immunohistochemistry for S100A4 (Abcam #ab27957, 1:300) and Ki67 (Master
Diagnostica #0003110QD, undiluted) was performed using an automated
immunostaining platform (Ventana discovery XT, Roche).

665

666 Immunoblotting

667 Cell pellets or frozen tumor tissues were lysed with JS lysis buffer (50 mM 668 HEPES, 150 mM NaCl, 1% Glycerol, 1% Triton X-100, 1.5 mM MgCl2, 5 mM EGTA) 669 and protein concentrations were determined by DC protein assay kit II (Bio-Rad 670 #5000112). Proteins were separated on house-made SDS-PAGE gels and transferred to 671 nitrocellulose membranes (Amersham #10600003). Membranes were incubated in 672 blocking buffer (5% milk in TBST) and then with primary antibody overnight at 4°C. The 673 following primary antibodies and respective dilutions were used: FLAG (Cell Signaling 674 Technology #2368S, 1:2000), FRA-1 (Santa Cruz #sc-183, 1:1000; #sc-605, 1:1000), 675 GFAP (Sigma-Aldrich #G3893, 1:5000), NF1 (Santa Cruz #sc-67, 1:500; Bethyl #A300-676 140A, 1:1000), OLIG2 (Millipore #AB9610, 1:2000), VIMENTIN (Cell Signaling 677 Technology #5741, 1:3000), p-ERK1/2 (T202/Y204) (Cell Signaling Technology, #9101, 678 1:2000/3000; Assay Designs #ADI-905-651, 1:250), ERK1/2 (Cell Signaling 679 Technology, #9102, 1:1000; Abcam #ab17942, 1:1000), p-MEK (S217/221) (Cell 680 Signaling Technology, #9154, 1:500/1000), MEK (Cell Signaling Technology, #9122 681 1:1000), CHI3L1 (Qidel #4815, 1:1000), p85 (Millipore #06-195, 1:10000), VINCULIN 682 (Sigma-Aldrich #V9131, 1:10000) and α-TUBULIN (Abcam #ab7291, 1:10000). Anti-683 mouse or rabbit-HRP-conjugated antibodies (Jackson ImmunoResearch, #115-035-003 684 and #111-035-003) were used to detect desired protein by chemiluminescence with ECL 685 Detection Reagent (Amersham, #RPN2106).

- 686
- 687

Reverse transcription quantitative PCR

RNA from NSCs and frozen tissue was isolated with TRIzol reagent (Invitrogen
#15596-026) according to the manufacturer's instructions. For reverse transcription PCR
(RT-PCR), 500 ng of total RNA was reverse transcribed using the High Capacity cDNA

Reverse Transcription Kit (Applied Biosystems #4368814). Quantitative PCR was performed using the SYBR Select Master Mix (Applied Biosystems #4472908) according to the manufacturer's instructions. qPCRs were run and the melting curves of the amplified products were used to determine the specificity of the amplification. The threshold cycle number for the genes analyzed was normalized to GAPDH. Mouse and human primer sequences are listed in Table S5.

RNA from BTSC cells was prepared using the RNeasy kit or the AllPrep
DNA/RNA Protein Mini Kit and used for first strand cDNA synthesis using random
primers and SuperscriptIII reverse transcriptase (Life Technologies #18080-085). Primer
sequences used in qRT-PCR with SYBR Green are listed in Table S5. Quantitative realtime PCR (qRT-PCR) STAT3 and CEBPB were performed using pre-validated TaqMan
assays (Applied Biosystems): STAT3: Hs01047580, CEBPB: Hs00270923 and 18s
rRNA: Hs99999901.

704

705 MTT assay

Cells were seeded in 96-well culture plates (1000 cells per well, 10 wells per cell not grown for 7 days. At each timepoint (days 1, 3, 5 and 7), cell viability was determined by MTT assay. Briefly, 10 μ L of 5 mg/mL MTT (Sigma-Aldrich #M5655) was added to each well and cells were incubated for 4 h before lysing with a formazan solubilization solution (10% SDS in 0.01 M HCl). Colorimetric intensity was quantified using a plate reader at 590 nm. Values were obtained after subtraction of matched blanks (medium only).

713

714 Cell cycle analysis: Propidium iodide (PI) staining

Cells were harvested and washed twice with PBS prior to fixation with 70% cold ethanol, added drop-wise to the cell pellet while vortexing. Fixed cells were then washed, first with 1% BSA in PBS, then with PBS only and stained overnight with 50 μ g/mL PI (Sigma-Aldrich #P4170) and 100 μ g/mL RNase A (Roche #10109142001) in PBS. Samples were acquired in a FACSCanto II cytometer (BD Biosciences) and data were analyzed using FlowJo software.

721

722 BrdU incorporation

723 Cells were pulse-labelled with 10 μ M BrdU (Sigma-Aldrich #B9285) for 2 h, 724 harvested and washed twice with PBS prior to fixation with 70% ethanol cold ethanol,

725 added drop-wise to the cell pellet while vortexing. DNA denaturation was performed by 726 incubating samples for 10 min on ice with 0.1 M HCl with 0.5% Tween-20 and samples 727 were then resuspended in water and boiled at 100°C for 10 min. Anti-BrdU-FITC 728 antibody (BD Biosciences #556028) was incubated according to manufacturer's protocol. 729 After washing with PBSTB (PBS with 0.5% Tween-20 and 1% BSA), samples were 730 resuspended in 25 µg/mL PI and 100 µg/mL RNase A diluted in PBS. Samples were 731 acquired in a FACSCanto II cytometer (BD Biosciences) and data were analyzed using 732 FlowJo software.

733

734 Immunofluorescence

735 Cells were plated in laminin-coated coverslips and fixed with 4% PFA for 15 min. 736 Cells were then permeabilized with 0.1% Triton X-100 in 0.2% BSA and coverslips were 737 washed and blocked with 10% donkey serum in 0.2% BSA for 1 h. The following primary antibodies were incubated overnight at 4°C: CD44 (BD Biosciences #550538, 1:100), 738 739 GFAP (Millipore #MAB360, 1:400) and OLIG2 (Millipore #AB9610, 1:100). Secondary 740 antibodies at 1:400 dilution (from Invitrogen, Alexa-Fluor anti-rabbit-488, anti-mouse-741 488 and anti-rat 594) were incubated for 1 h at RT and after washing coverslips were 742 incubated for 4 min with DAPI (1:4000, Sigma-Aldrich #D8417) and mounted with 743 ProLong Gold Antifade reagent (Invitrogen #P10144).

Fluorescence signal was quantified as the ratio of green/red pixel area relative to
DAPI pixel area per field of view, in a total of 36 fields per condition analyzed.

746

747 Neurosphere formation assay and limiting dilution analysis

748 Neurospheres were dissociated and passed through a 40 µm mesh filter to 749 eliminate non-single cells. Decreasing cell densities were plated in ultra-low attachment 750 96-well plates (Corning #CLS3474) and fresh medium was added every 3-4 days. The 751 number of positive wells for presence of spheres was counted 2 weeks after plating. 752 Limiting dilution analysis was performed using ELDA R package 753 (http://bioinf.wehi.edu.au/software/elda/).

754

755 RNA-sequencing and analysis on mouse NSCs

One microgram of total RNA from the samples was used. cDNA libraries were prepared using the "QuantSeq 3' mRNA-Seq Library Prep Kit (FWD) for Illumina" (Lexogen #015) by following manufacturer instructions. Library generation is initiated

759 by reverse transcription with oligo(dT) priming, and a second strand synthesis is 760 performed from random primers by a DNA polymerase. Primers from both steps contain 761 Illumina-compatible sequences. Adapter-ligated libraries were completed by PCR, 762 applied to an Illumina flow cell for cluster generation and sequenced on an Illumina 763 HiSeq 2500 by following manufacturer's protocols. Sequencing read alignment and 764 quantification and differential gene expression analysis was performed in the Bluebee 765 Genomics Platform, a cloud-based service provider (<u>www.bluebee.com</u>). Briefly, reads 766 were first trimmed with bbduk from BBTools (BBMap - Bushnell B, 767 https://sourceforge.net/projects/bbmap/) to remove adapter sequences and polyA tails. 768 Trimmed reads were aligned to the GRCm38/mm10 genome assembly with STAR v 2.5 769 (Dobin et al., 2013). Read counting was performed with HTSeq (Anders et al., 2015). 770 Differential gene expression analysis was performed with DESeq2 (Love et al., 2014). 771 The list of stem/differentiation markers was compiled by combining a previously 772 described gene list (Sandberg et al. 2013) with other markers (Bazzoli et al., 2012). 773 GSEAPreranked (Subramanian et al., 2005) was used to perform gene set enrichment 774 analysis of the described indicated signatures on a pre-ranked gene list, setting 1000 gene 775 set permutations.

- 776
- 777

Osteogenesis Differentiation Assay

778 The osteogenesis differentiation assay was performed using the StemPro 779 Osteogenesis Differentiation Kit (Life Technologies #A1007201) according to the manufacturer's instructions. Briefly, 5×10^3 cells/cm² were seeded on laminin-coated 780 781 glass coverslips in a 24-well cell culture plate. Cells were incubated in MSC Growth 782 Medium at 37°C, 5% CO₂ for 21 days, replacing the medium every 4 days. Cells were 783 then fixed with 4% formaldehyde, stained with Alizarin Red S solution (pH 4.2) and 784 mounted on microscope slides. Pictures were acquired using an Axiovert Microscope 785 (Zeiss).

786

787 Active Ras pull down assay

Active Ras pull down assay was performed using Active Ras pull down assay kit (ThermoFisher Scientific #16117) according to the manufacturer's instructions. Briefly, cells were grown in 10 cm plates at 80-90% confluency in presence or absence of growth factors (EGF, FGF and LIF), and lysed with the provided buffer. Lysates were incubated

with either GDP or GTP for 30 min followed by precipitation with GST-Raf1-RBD.
Western blot was performed with the provided anti-RAS antibody (1:250).

794

795 Chromatin preparation and FRA-1 ChIP

796 BTSC cells were collected at 2×10^6 cells confluency, washed in PBS and fixed by 797 addition of 1% formaldehyde for 20 min at room temperature. The cells were resuspended 798 in 2 mL Lysis Buffer (50 mM Tris pH 7.5; 1 mM EDTA pH 8.0; 1% Triton; 0.1% Na-799 deoxycholate; 150 mM NaCl; protease inhibitors) on ice for 20 min. The suspension was 800 sonicated in a cooled Bioruptor Pico (Diagenode), and cleared by centrifugation for 10 801 min at 13000 rpm. The chromatin (DNA) concentration was quantified using NanoDrop 802 (Thermo Scientific) and the sonication efficiency monitored on an agarose gel. Protein 803 A/G plus-agarose beads (Santa Cruz #sc-2003) were blocked with sonicated salmon 804 sperm (ThermoFisher #AM9680, 200 mg/mL beads) and BSA (NEB #B9000S, 250 805 mg/mL beads) in dilution buffer (0.5% NP40; 200 mM NaCl; 50 mM Tris pH 8.0; 806 protease inhibitors) for 2 h at room temperature. The chromatin was pre-cleared with 80 807 µL of blocked beads for 1 h at 4°C. Pre-cleared chromatin was incubated with 5 µg of 808 FRA-1 antibody (Santa Cruz #sc-605) overnight at 4°C, then with 40 µL of blocked beads 809 for further 2 h at 4°C. Control mock immunoprecipitation was performed with blocked 810 beads. The beads were washed 1× with Wash1 (20 mM Tris pH 7.5; 2 mM EDTA pH 811 8.0; 1% Triton; 0.1% SDS; 150 mM NaCl), 1× with Wash2 (20 mM Tris pH 7.5; 2 mM 812 EDTA pH 8.0; 1% Triton; 0.1% SDS; 500 mM NaCl), 1× with LiCl Wash (20 mM Tris 813 pH 7.5; 1 mM EDTA pH 8.0; 1% NP40; 1% deoxycholate; 250 mM LiCl) and 2× in TE 814 (10 mM Tris pH 7.5; 1 mM EDTA). The immuno-complexes were eluted by two 15 min 815 incubations at 30°C with 100 µL Elution buffer (1% SDS, 100 mM NaHCO₃), and de-816 crosslinked overnight at 65°C in the presence of 10 U RNase A (Ambion #AM9780). The 817 immune-precipitated DNA was then purified with the QIAquick PCR purification kit 818 (Qiagen #28104) according to manufacturer's protocol and analyzed by quantitative real-819 time PCR.

820

821 Statistical analysis

All statistical analyses were performed using R programming language. Statistical differences between groups in the *in vitro* assays were assessed by unpaired two-tailed Student's t tests, unless otherwise specified.

Kaplan–Meier survival curves were produced with GraphPad Prism and P values
were generated using the Log-Rank statistics.

- Results are presented as mean \pm standard deviation (SD), and statistical significance was defined as P \leq 0.05 for a 95% confidence interval.
- 829

830 Data and code availability

831 The accession numbers for data reported in this paper are GEO: GSE137310

832 (Freiburg BTSCs) and GSE138010 (mouse NSCs). All the code used for data analysis

and plots generation will be available at: https://github.com/squatrim/Marques2019.

834

835

836 **References**

- 837 Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq--a Python framework to work with
- high-throughput sequencing data. Bioinformatics 31, 166–169.
- Andreolas, C., Kalogeropoulou, M., Voulgari, A., and Pintzas, A. (2008). Fra-1
- 840 regulates vimentin during Ha-RAS-induced epithelial mesenchymal transition in
- human colon carcinoma cells. Int. J. Cancer 122, 1745–1756.
- 842 Annibali, D., Whitfield, J.R., Favuzzi, E., Jauset, T., Serrano, E., Cuartas, I., Redondo-
- 843 Campos, S., Folch, G., Gonzàlez-Juncà, A., Sodir, N.M., et al. (2014). Myc inhibition is
- 844 effective against glioma and reveals a role for Myc in proficient mitosis. Nat. Commun.
- 845 5, 1–11.
- 846 Bakiri, L., MacHo-Maschler, S., Custic, I., Niemiec, J., Guió-Carrión, A., Hasenfuss,
- 847 S.C., Eger, A., Müller, M., Beug, H., and Wagner, E.F. (2015). Fra-1/AP-1 induces
- EMT in mammary epithelial cells by modulating Zeb1/2 and TGF β expression. Cell
- 849 Death Differ. 22, 336–350.
- Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst, M.W.,
- Bigner, D.D., and Rich, J.N. (2006). Glioma stem cells promote radioresistance by
- preferential activation of the DNA damage response. Nature 444, 756–760.
- 853 Basso, K., Margolin, A.A., Stolovitzky, G., Klein, U., Dalla-Favera, R., and Califano,
- A. (2005). Reverse engineering of regulatory networks in human B cells. Nat. Genet.
 37, 382–390.
- 856 Bazzoli, E., Pulvirenti, T., Oberstadt, M.C., Perna, F., Wee, B., Schultz, N., Huse, J.T.,
- Fomchenko, E.I., Voza, F., Tabar, V., et al. (2012). MEF Promotes Stemness in the
- Pathogenesis of Gliomas. Cell Stem Cell 11, 836–844.
- 859 Belteki, G., Haigh, J., Kabacs, N., Haigh, K., Sison, K., Costantini, F., Whitsett, J.,
- 860 Quaggin, S.E., and Nagy, A. (2005). Conditional and inducible transgene expression in
- 861 mice through the combinatorial use of Cre-mediated recombination and tetracycline
- 862 induction. Nucleic Acids Res. 33, 1–10.
- 863 Bhat, K.P.L., Salazar, K.L., Balasubramaniyan, V., Wani, K., Heathcock, L.,
- Hollingsworth, F., James, J.D., Gumin, J., Diefes, K.L., Kim, S.H., et al. (2011). The
- 865 transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant

- 866 glioma. Genes Dev. 25, 2594–2609.
- 867 Bhat, K.P.L., Balasubramaniyan, V., Vaillant, B., Ezhilarasan, R., Hummelink, K.,
- 868 Hollingsworth, F., Wani, K., Heathcock, L., James, J.D., Goodman, L.D., et al. (2013).
- 869 Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in
- 870 Glioblastoma. Cancer Cell 24, 331–346.
- Bowman, R.L., Wang, Q., Carro, A., Verhaak, R.G.W., and Squatrito, M. (2017).
- 872 GlioVis data portal for visualization and analysis of brain tumor expression datasets.
- 873 Neuro. Oncol. 19, 139–141.
- 874 Brennan, C.W., Verhaak, R.G.W., McKenna, A., Campos, B., Noushmehr, H., Salama,
- 875 S.R., Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., et al. (2013). The
- somatic genomic landscape of glioblastoma. Cell 155, 462–477.
- 877 Carro, M.S., Lim, W.K., Alvarez, M.J., Bollo, R.J., Zhao, X., Snyder, E.Y., Sulman,
- 878 E.P., Anne, S.L., Doetsch, F., Colman, H., et al. (2010). The transcriptional network for
- mesenchymal transformation of brain tumours. Nature *463*, 318–325.
- 880 Casalino, L., De Cesare, D., and Verde, P. (2003). Accumulation of Fra-1 in ras-
- 881 Transformed Cells Depends on Both Transcriptional Autoregulation and MEK-
- 882 Dependent Posttranslational Stabilization. Mol. Cell. Biol. 23, 4401–4415.
- 883 Castro, M.A.A., de Santiago, I., Campbell, T.M., Vaughn, C., Hickey, T.E., Ross, E.,
- Tilley, W.D., Markowetz, F., Ponder, B.A.J., and Meyer, K.B. (2016). Regulators of
- genetic risk of breast cancer identified by integrative network analysis. Nat. Genet. 48,
 12–21.
- 887 Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray, B.A.,
- 888 Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S.M., et al. (2016). Molecular
- 889 Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse
- 890 Glioma. Cell *164*, 550–563.
- 891 Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., and Parada, L.F.
- 892 (2012). A restricted cell population propagates glioblastoma growth after chemotherapy.
- 893 Nature 488, 522–526.
- 894 Chiappetta, G., Ferraro, A., Botti, G., Monaco, M., Pasquinelli, R., Vuttariello, E.,

- Arnaldi, L., Di Bonito, M., D'Aiuto, G., Pierantoni, G.M., et al. (2007). FRA-1 protein
- 896 overexpression is a feature of hyperplastic and neoplastic breast disorders. BMC Cancer
- 897 7, 17.
- 898 Cooper, L.A.D., Gutman, D.A., Chisolm, C., Appin, C., Kong, J., Rong, Y., Kurc, T.,
- 899 Van Meir, E.G., Saltz, J.H., Moreno, C.S., et al. (2012). The Tumor Microenvironment
- 900 Strongly Impacts Master Transcriptional Regulators and Gene Expression Class of
- 901 Glioblastoma. Am. J. Pathol. 180, 2108–2119.
- 902 Debinski, W., and Gibo, D.M. (2005). Fos-related antigen 1 modulates malignant
- 903 features of glioma cells. Mol. Cancer Res. *3*, 237–249.
- 904 Diesch, J., Sanij, E., Gilan, O., Love, C., Tran, H., Fleming, N.I., Ellul, J., Amalia, M.,
- 905 Haviv, I., Pearson, R.B., et al. (2014). Widespread FRA1-Dependent Control of
- 906 Mesenchymal Transdifferentiation Programs in Colorectal Cancer Cells. PLoS One 9,
- 907 1–11.
- 908 Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P.,
- 909 Chaisson, M., and Gingeras, T.R. (2013). STAR: ultrafast universal RNA-seq aligner.
- 910 Bioinformatics 29, 15–21.
- Eferl, R., and Wagner, E.F. (2003). AP-1: A double-edged sword in tumorigenesis. Nat.
 Rev. Cancer *3*, 859–868.
- 913 Fedele, M., Cerchia, L., Pegoraro, S., Sgarra, R., and Manfioletti, G. (2019). Proneural-
- 914 Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in
- 915 Glioblastoma. Int. J. Mol. Sci. 20, 2746.
- 916 Fedele, V., Dai, F., Masilamani, A.P., Heiland, D.H., Kling, E., Gätjens-Sanchez, A.M.,
- 917 Ferrarese, R., Platania, L., Soroush, D., Kim, H., et al. (2017). Epigenetic Regulation of
- 2BTB18 Promotes Glioblastoma Progression. Mol. Cancer Res. 15, 998–1011.
- 919 Fletcher, M.N.C., Castro, M.A.A., Wang, X., de Santiago, I., O'Reilly, M., Chin, S.-F.,
- 920 Rueda, O.M., Caldas, C., Ponder, B.A.J., Markowetz, F., et al. (2013). Master regulators
- 921 of FGFR2 signalling and breast cancer risk. Nat. Commun. 4, 2464.
- 922 Friedmann-Morvinski, D., Bushong, E.A., Ke, E., Soda, Y., Marumoto, T., Singer, O.,
- 923 Ellisman, M.H., and Verma, I.M. (2012). Dedifferentiation of neurons and astrocytes by

- 924 oncogenes can induce gliomas in mice. Science *338*, 1080–1084.
- 925 Gao, X.-Q., Ge, Y.-S., Shu, Q.-H., and Ma, H.-X. (2017). Expression of Fra-1 in human
- 926 hepatocellular carcinoma and its prognostic significance. Tumour Biol. 39,

- 928 Günther, H.S., Schmidt, N.O., Phillips, H.S., Kemming, D., Kharbanda, S., Soriano, R.,
- 929 Modrusan, Z., Meissner, H., Westphal, M., and Lamszus, K. (2008). Glioblastoma-
- 930 derived stem cell-enriched cultures form distinct subgroups according to molecular and
- phenotypic criteria. Oncogene 27, 2897–2909.
- 932 Halliday, J., Helmy, K., Pattwell, S.S., Pitter, K.L., LaPlant, Q., Ozawa, T., and
- Holland, E.C. (2014). In vivo radiation response of proneural glioma characterized by
- 934 protective p53 transcriptional program and proneural-mesenchymal shift. Proc. Natl.
- 935 Acad. Sci. 111, 5248–5253.
- 936 Hambardzumyan, D., Amankulor, N.M., Helmy, K.Y., Becher, O.J., and Holland, E.C.
- 937 (2009). Modeling Adult Gliomas Using RCAS/t-va Technology. Transl. Oncol. 2, 89–
- 938 95.
- 939 Hasenfuss, S.C., Bakiri, L., Thomsen, M.K., Hamacher, R., and Wagner, E.F. (2014).
- 940 Activator protein 1 transcription factor fos-related antigen 1 (fra-1) is dispensable for
- 941 murine liver fibrosis, but modulates xenobiotic metabolism. Hepatology 59, 261–273.
- Holland, E.C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R.E., and Fuller, G.N.
- 943 (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma
- 944 formation in mice. Nat. Genet. 25, 55–57.
- 945 Koschmann, C., Calinescu, A.-A., Nunez, F.J., Mackay, A., Fazal-Salom, J., Thomas,
- 946 D., Mendez, F., Kamran, N., Dzaman, M., Mulpuri, L., et al. (2016). ATRX loss
- 947 promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.
- 948 Sci. Transl. Med. 8, 328ra28.
- 949 Lau, E.Y.T., Lo, J., Cheng, B.Y.L., Ma, M.K.F., Lee, J.M.F., Ng, J.K.Y., Chai, S., Lin,
- 950 C.H., Tsang, S.Y., Ma, S., et al. (2016). Cancer-Associated Fibroblasts Regulate
- 951 Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-
- 952 Met/FRA1/HEY1 Signaling. Cell Rep. 15, 1175–1189.

^{927 1010428317709635.}

- 953 Liu, H., Ren, G., Wang, T., Chen, Y., Gong, C., Bai, Y., Wang, B., Qi, H., Shen, J.,
- 254 Zhu, L., et al. (2015). Aberrantly expressed Fra-1 by IL-6/STAT3 transactivation
- 955 promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition.
- 956 Carcinogenesis *36*, 459–468.
- 957 Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and
- dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550.
- 959 Mack, S.C., Singh, I., Wang, X., Hirsch, R., Wu, Q., Villagomez, R., Bernatchez, J.A.,
- 960 Zhu, Z., Gimple, R.C., Kim, L.J.Y., et al. (2019). Chromatin landscapes reveal
- 961 developmentally encoded transcriptional states that define human glioblastoma. J. Exp.
- 962 Med. 216, 1071–1090.
- 963 Mani, S.A., Guo, W., Liao, M.-J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M.,
- Reinhard, F., Zhang, C.C., Shipitsin, M., et al. (2008). The epithelial-mesenchymal
- transition generates cells with properties of stem cells. Cell 133, 704–715.
- Mansuy, I.M., and Bujard, H. (2000). Tetracycline-regulated gene expression in the
 brain. Curr. Opin. Neurobiol. *10*, 593–596.
- 968 Mao, P., Joshi, K., Li, J., Kim, S.-H., Li, P., Santana-Santos, L., Luthra, S., Chandran,
- 969 U.R., Benos, P. V., Smith, L., et al. (2013). Mesenchymal glioma stem cells are
- 970 maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3.
- 971 Proc. Natl. Acad. Sci. 110, 8644–8649.
- McCormick, F. (1990). GAP as ras effector or negative regulator? Mol. Carcinog. *3*,
 185–187.
- 974 Muñoz, D.M., Tung, T., Agnihotri, S., Singh, S., Guha, A., Zadeh, G., and Hawkins, C.
- 975 (2013). Loss of p53 cooperates with K-ras activation to induce glioma formation in a
- 976 region-independent manner. Glia 61, 1862–1872.
- 977 Neftel, C., Laffy, J., Filbin, M.G., Hara, T., Shore, M.E., Rahme, G.J., Richman, A.R.,
- 978 Silverbush, D., Shaw, M.L., Hebert, C.M., et al. (2019). An Integrative Model of
- 979 Cellular States, Plasticity, and Genetics for Glioblastoma. Cell 178, 835-849.e21.
- 980 Oldrini, B., Curiel-García, Á., Marques, C., Matia, V., Uluçkan, Ö., Graña-Castro, O.,
- 981 Torres-Ruiz, R., Rodriguez-Perales, S., Huse, J.T., and Squatrito, M. (2018). Somatic

- 982 genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor
- 983 modeling. Nat. Commun. 9, 1466.
- 984 Ozawa, T., Riester, M., Cheng, Y.K., Huse, J.T., Squatrito, M., Helmy, K., Charles, N.,
- 985 Michor, F., and Holland, E.C. (2014). Most human non-GCIMP glioblastoma subtypes
- 986 evolve from a common proneural-like precursor glioma. Cancer Cell 26, 288–300.
- 987 Patel, A.P., Tirosh, I., Trombetta, J.J., Shalek, A.K., Gillespie, S.M., Wakimoto, H.,
- 988 Cahill, D.P., Nahed, B. V, Curry, W.T., Martuza, R.L., et al. (2014). Single-cell RNA-
- seq highlights intratumoral heterogeneity in primary glioblastoma. Science *344*, 1396–
 1401.
- 991 Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra,
- A., Nigro, J.M., Colman, H., Soroceanu, L., et al. (2006). Molecular subclasses of high-
- 993 grade glioma predict prognosis, delineate a pattern of disease progression, and resemble
- stages in neurogenesis. Cancer Cell 9, 157–173.
- 995 Ricci-Vitiani, L., Pallini, R., Larocca, L.M., Lombardi, D.G., Signore, M., Pierconti, F.,
- 996 Petrucci, G., Montano, N., Maira, G., and De Maria, R. (2008). Mesenchymal
- 997 differentiation of glioblastoma stem cells. Cell Death Differ. 15, 1491–1498.
- 998 Sandberg, C.J., Altschuler, G., Jeong, J., Strømme, K.K., Stangeland, B., Murrell, W.,
- 999 Grasmo-Wendler, U.H., Myklebost, O., Helseth, E., Vik-Mo, E.O., et al. (2013).
- 1000 Comparison of glioma stem cells to neural stem cells from the adult human brain
- 1001 identifies dysregulated Wnt- signaling and a fingerprint associated with clinical
- 1002 outcome. Exp. Cell Res. *319*, 2230–2243.
- 1003 Sottoriva, A., Spiteri, I., Piccirillo, S.G.M., Touloumis, A., Collins, V.P., Marioni, J.C.,
- 1004 Curtis, C., Watts, C., and Tavare, S. (2013). Intratumor heterogeneity in human
- 1005 glioblastoma reflects cancer evolutionary dynamics. Proc. Natl. Acad. Sci. 110, 4009–
- 1006 4014.
- 1007 Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A.,
- 1008 Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. (2005). Gene set
- 1009 enrichment analysis: a knowledge-based approach for interpreting genome-wide
- 1010 expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102, 15545–15550.
- 1011 Tam, W.L., and Weinberg, R.A. (2013). The epigenetics of epithelial-mesenchymal

- 1012 plasticity in cancer. Nat. Med. 19, 1438–1449.
- 1013 Tam, W.L., Lu, H., Buikhuisen, J., Soh, B.S., Lim, E., Reinhardt, F., Wu, Z.J., Krall,
- 1014 J.A., Bierie, B., Guo, W., et al. (2013). Protein kinase C alpha is a central signaling
- 1015 node and therapeutic target for breast cancer stem cells. Cancer Cell 24, 347–364.
- 1016 The Cancer Genome Atlas Research Network (2008). Comprehensive genomic
- 1017 characterization defines human glioblastoma genes and core pathways. Nature 455,1018 1061–1068.
- 1019 Tso, C.-L., Shintaku, P., Chen, J., Liu, Q., Liu, J., Chen, Z., Yoshimoto, K., Mischel,
- 1020 P.S., Cloughesy, T.F., Liau, L.M., et al. (2006). Primary Glioblastomas Express
- 1021 Mesenchymal Stem-Like Properties. Mol. Cancer Res. 4, 607–619.
- 1022 Uhrbom, L., Dai, C., Celestino, J.C., Rosenblum, M.K., Fuller, G.N., and Holland, E.C.
- 1023 (2002). Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural
- 1024 progenitors to generate glioblastomas of various morphologies depending on activated
- 1025 Akt. Cancer Res. 62, 5551–5558.
- 1026 Usui, A., Hoshino, I., Akutsu, Y., Sakata, H., Nishimori, T., Murakami, K., Kano, M.,
- 1027 Shuto, K., and Matsubara, H. (2012). The molecular role of Fra-1 and its prognostic
- 1028 significance in human esophageal squamous cell carcinoma. Cancer 118, 3387–3396.
- 1029 Vallejo, A., Perurena, N., Guruceaga, E., Mazur, P.K., Martinez-Canarias, S., Zandueta,
- 1030 C., Valencia, K., Arricibita, A., Gwinn, D., Sayles, L.C., et al. (2017). An integrative
- 1031 approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and
- 1032 pancreatic cancer. Nat. Commun. 8.
- 1033 Verde, P., Casalino, L., Talotta, F., Yaniv, M., and Weitzman, J.B. (2007). Deciphering
- 1034 AP-1 function in tumorigenesis: fra-ternizing on target promoters. Cell Cycle *6*, 2633–
- 1035 2639.
- 1036 Verhaak, R.G.W., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D.,
- 1037 Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., et al. (2010). Integrated Genomic
- 1038 Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by
- 1039 Abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110.
- 1040 Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D.I.S., Zairis, S., Abate,

- F., Liu, Z., Elliott, O., Shin, Y.-J., et al. (2016). Clonal evolution of glioblastoma under
 therapy. Nat. Genet. 48, 768–776.
- 1043 Wang, L., Babikir, H., Muller, S., Yagnik, G., Shamardani, K., Catalan, F., Kohanbash,
- 1044 G., Alvarado, B., Di Lullo, E., Kriegstein, A., et al. (2019). The phenotypes of
- proliferating glioblastoma cells reside on a single axis of variation. Cancer Discov. CD-1046 19-0329.
- 1047 Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A.C., Lyu,
- 1048 S., Li, P., Li, Y., et al. (2017). Tumor Evolution of Glioma-Intrinsic Gene Expression
- Subtypes Associates with Immunological Changes in the Microenvironment. CancerCell *32*, 42-56.e6.
- 1051 Wu, J., Ji, A., Wang, X., Zhu, Y., Yu, Y., Lin, Y., Liu, Y., Li, S., Liang, Z., Xu, X., et
- al. (2015). MicroRNA-195-5p, a new regulator of Fra-1, suppresses the migration and
- 1053 invasion of prostate cancer cells. J. Transl. Med. 13, 289.
- 1054 Xu, H., Jin, X., Yuan, Y., Deng, P., Jiang, L., Zeng, X., Li, X.-S., Wang, Z.-Y., and
- Chen, Q.-M. (2017). Prognostic value from integrative analysis of transcription factors
 c-Jun and Fra-1 in oral squamous cell carcinoma: a multicenter cohort study. Sci. Rep.
- 1057 7, 7522.
- 1058 Ye, X., Tam, W.L., Shibue, T., Kaygusuz, Y., Reinhardt, F., Ng Eaton, E., and
- 1059 Weinberg, R.A. (2015). Distinct EMT programs control normal mammary stem cells
- and tumour-initiating cells. Nature 525, 256–260.

1061

1062

bioRxiv preprint first posted online Nov. 7, 2019; doi: http://dx.doi.org/10.1101/834531. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.




Figure 1. *FOSL1* is a master regulator of the glioma-intrinsic MES transcriptional signature. A) Principal Component (PC) analysis of the BTSCs expression dataset. B) Heatmap of the top 100 differentially expressed genes between MES and Non-MES BTSCs. C) One-tail GSEA of the top 5 scoring TFs in the MRA. D) *FOSL1* mRNA expression in the BTSCs dataset. Student's t test, $*P \le 0.05$, $***P \le 0.001$. E) *FOSL1* mRNA expression in the TCGA dataset. Tumors were separated according to their molecular subtype classification. Student's t test, $***P \le 0.001$. F) Kaplan-Meier survival curves of the IDH-wt GBM TCGA tumors stratified based on *FOSL1* expression. *See also Figure S1*.




Figure 2. *NF1* is a functional modulator of MES transcriptional signature and *FOSL1* expression. A) Heatmap of the subtype ssGSEA scores and *NF1* genetic alterations of the IDH-wt GBM TCGA tumors. B) Frequency of *NF1* alterations in MES and Non-MES GBMs. Colors are as in panel A. C) and D) *FOSL1* mRNA expression in the TCGA dataset. Tumors were separated according to either *NF1* alterations (C) or transcriptional subtypes (D). Colors are as in panel A. Student's t test, **P ≤ 0.01 , ***P ≤ 0.001 . E) GSEA of BTSC 233 MES cells transduced with NF1-GRD expressing lentivirus versus Ctrl. Gene signatures from Wang and Phillips studies were analyzed (MES, *left panels*; PN, *right panels*). ES = Enrichment score. F) Western blot analysis of whole-cell-extract of BTSC 233 cells showing CHI3L1 mesenchymal marker expression upon NF1-GRD transduced as indicated above. Alzarin Red staining indicates osteogenesis differentiation. Scale bar represents 200 µm. H) Western blot analysis of whole-cell-extract of proneural BTSC 3021 cells transduced with either *NF1* (sh*NF1*) or control (shCtrl) shRNAs. I) GSEA of BTSC 3021 transduced with sh*NF1* versus Ctrl. J) and K) qRT-PCR analysis of *FOSL1* expression upon NF1-GRD overexpression in BTSC 232 and BTSC 233 cells (J) or NF1 knockdown in 3021 and 3047 cells (K). Data are presented as mean \pm SD (n=3), normalized to 18s rRNA expression; Student's t test, *P ≤ 0.05 , **P ≤ 0.01 , ***P ≤ 0.001 . *See also Figure S2-S3*.




Figure 3. *Fosl1* is induced by MAPK kinase activation and is required for MES gene expression. A) Western blot analysis using the specified antibodies of p53-null NSCs, parental and infected with sg*Nf1*, sh*Nf1* and *Kras^{G12V}*; Vinculin used as loading control. **B)** mRNA expression of *Fosl1* and MES genes (*Plau, Plaur, Timp1* and *Cd44*), in infected p53-null NSCs, compared to parental cells (not infected). Data from a representative of two experiments are presented as mean \pm SD (n=3), normalized to *Gapdh* expression. Student's t test, relative to parental cells: ns = not significant, *P \leq 0.05, **P \leq 0.01, ***P \leq 0.001. **C)** FRA-1 expression detected by Western blot in p53-null *Kras^{G12V}* NSCs upon transduction with sgRNAs targeting *Fosl1*, after selection with 1 µg/mL puromycin; Vinculin used as loading control. **D)** GSEA of p53-null *Kras^{G12V}* sg*Fosl1*_1 versus sgCtrl NSCs. Gene signatures from Wang and Phillips studies were analyzed (MES, *left panels*; PN, *right panels*). **E)** and **F)** mRNA expression of MES and PN genes, respectively, in sgCtrl and sg*Fosl1*_1 p53-null *Kras^{G12V}* NSCs. Data from a representative of two experiments are presented as mean \pm SD (n=3), normalized to *Gapdh* expression. Student's t test, relative to sgCtrl: *P \leq 0.05; **P \leq 0.01; ***P \leq 0.001.




Figure 4. *Fosl1* knock-out impairs cell growth and stemness *in vitro* and increases survival in a xenograft model. A) Cell viability of control and *Fosl1* KO p53-null *Kras*^{G12V} NSCs measured by MTT assay; absorbance values were normalized to day 1. Data from a representative of three independent experiments are presented as mean \pm SD (n=10). Student's t test on day 7, relative to sgCtrl: ***P \leq 0.001. B) Quantification of cell cycle populations of control and *Fosl1* KO p53-null *Kras*^{G12V} NSCs by flow cytometry analysis of PI staining. Data from a representative of two independent experiments are presented as mean \pm SD (n=3). Student's t test, relative to sgCtrl: *P \leq 0.05; **P \leq 0.01; ***P \leq 0.001. C) A representative limiting dilution experiment on p53-null *Kras*^{G12V} sgCtrl and sg*Fosl1*_1 NSCs, calculated with extreme limiting dilution assay (ELDA) analysis; P < 0.0001. D) Heatmap of expression of stem cell (yellow) and lineage-specific (neuronal – purple, astrocytic – green and oligodendrocytic – orange) genes, comparing sgCtrl and sg*Fosl1*_1 p53-null *Kras*^{G12V} NSCs. E) Quantification of pixel area (fold change

relative to sgCtrl) of CD44, GFAP and OLIG2 relative to DAPI pixel area per field of view in control and *Fosl1* KO p53-null *Kras*^{G12V} NSCs. Data from a representative of two independent experiments; Student's t test, relative to sgCtrl: ***P \leq 0.001. **F**) Kaplan-Meier survival curves of *nu/nu* mice injected with p53-null *Kras*^{G12V} sgCtrl (n=9) and sg*Fosl1*_1 (n=6) NSCs. Log-rank P = 0.0263. **G**) Western blot analysis using the indicated antibodies of 4 sgCtrl and 4 sg*Fosl1*_1 tumors (showing low or no detectable expression of FRA-1); Vinculin used as loading control. **H**) Representative images of IHCs using the indicated antibodies. Scale bars represent 100 µm. **I**) mRNA expression of MES genes in the samples sgCtrl–T4 (higher FRA-1 expression) and sg*Fosl1*_1–T3 and –T4 (no detectable FRA-1 expression). **J**) mRNA expression of PN genes in samples as in (H). Data from a representative of two experiments are presented as mean ± SD (n=3), normalized to *Gapdh* expression. Student's t test for sg*Fosl1*_1 tumors, relative to sgCtrl–T4: ns = not significant, *P \leq 0.00, **P \leq 0.01, ***P \leq 0.001. *See also Figure S4*.

bioRxiv preprint first posted online Nov. 7, 2019; doi: http://dx.doi.org/10.1101/834531. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.




Figure 5. Fosl1 overexpression upregulates the MGS and induces larger tumors in vivo. A) Western blot analysis of FRA-1 and Flag expression on Fosl1^{tetON} and Fosl1^{WT} NSCs derived from Kras^{LSLG12V}; Trp53^{lox}; ROSA26^{LSLrtTA-} IRES-EGFP; Collal^{TetO-Fosl1} mice, upon in vitro infection with Cre and induction of Fosl1 overexpression with 1 µg/mL Dox for 72 h; Vinculin used as loading control. **B**) mRNA expression of *Fosl1* and MES genes in *Fosl1^{tetON}* p53-null Kras^{G12V} cells upon 72 h induction with 1 µg/mL Dox. C) mRNA expression of PN genes in Fosl1^{tetON} p53-null *Kras^{G12V}* cells upon 72 h induction with 1 μ g/mL Dox. **D**) Quantification of tumor area (μ m²) of –Dox and +Dox tumors (n=8/8). For each mouse, the brain section on the H&E slide with a larger tumor was considered and quantified using the ZEN software (Zeiss). E) Western blot detection of FRA-1 expression in tumorspheres derived from a control (-Dox) tumor. Tumorspheres were isolated and kept without Dox until first passage, when 1 µg/mL Dox was added and kept for 19 days (+Dox in vitro). F) mRNA expression of Fosl1 and MES genes in tumorspheres in absence or presence of Dox for 19 days. G) mRNA expression of PN genes in tumorspheres in absence or presence of Dox for 19 days. H) Western blot detection of FRA-1 expression in tumorspheres derived from a Fosl1 overexpressing (+Dox) tumor. Tumorspheres were isolated and kept with 1 µg/mL Dox until first passage, when Dox was removed for 19 days (-Dox in vitro). I) mRNA expression of Fosl1 and MES genes in tumorspheres in presence or absence of Dox for 19 days. J) mRNA expression of PN genes in tumorspheres in presence or absence of Dox for 19 days. gPCR data from a representative of two experiments are presented as mean \pm SD (n=3), normalized to Gapdh expression. Student's t test, relative to the respective control (-Dox in B, C, F and G; +Dox in I and J): ns = not significant, $*P \le 0.05$, $**P \le 0.01$, $***P \le 0.001$. See also Figure S5.




Figure 6. FOSL1 silencing in a patient-derived MES tumor stem cell line decreases cell growth, stemness and MGS in vitro. A) Western blot analysis using the specified antibodies of human brain tumor stem cell lines. characterized as Non-MES (*left*) and MES (*right*). B) Western blot detection of FRA-1 in MES BTSC 349 upon transduction with inducible shRNAs targeting GFP (control) and FOSL1, analyzed after 3 and 7 days of Dox treatment; Vinculin used as loading control. C) Cell growth of BTSC 349 shGFP and shFOSL1, in absence or presence of Dox, measured by MTT assay; absorbance values were normalized to day 1. Data from a representative of three independent experiments are presented as mean \pm SD (n=15). Student's t test on day 7, relative to shFOSL1 -Dox: ***P ≤ 0.001 . D) Representative limiting dilution analysis on BTSC 349 sh*FOSL1*, in presence or absence of Dox, calculated with extreme limiting dilution assay (ELDA) analysis; P < 0.0001. E) mRNA expression of FOSL1 and MES genes in BTSC 349 shFOSL1 in absence or presence of Dox for 3 days. Data from a representative of three experiments are presented as mean \pm SD (n=3), normalized to GAPDH expression. Student's t test, relative to –Dox: ns = not significant, *P ≤ 0.05 , **P ≤ 0.01 , ***P ≤ 0.001 . F) Scatter plot of H3K27Ac signal for Non-Mes and MES BTSCs (from Mack et al., 2019) on FOSL1/FRA-1 peaks calculated using MACS on ENCODE samples (see methods). Blue probes represent statistically significant difference in H3K27Ac signal between Non-Mes and MES BTSCs. Violet trendline indicates a custom regression calculated by a Kolmorogov-Smirnov test, adj-P < 0.05, z > 0.05, z0.5. G) Principal component analysis of H3K27Ac of FOSL1/FRA-1 enrichment over FOSL1/FRA-1 binding sites for the indicated samples. H) Heatmap of ChIP-seq enrichment of FOSL1/FRA-1 or OLIG2 binding sites for the indicated profiles. I) IGV browser view of the PLAU, CD44 and OLIG2 loci of selected profiles. J) Representative ChIP experiment in BTSC 349 cells. The panel shows FRA-1 binding to the promoter of a subset of mesenchymal targets (n=3 PCR replicates) expressed as percentage of the initial DNA amount in the immune-precipitated fraction. NANOG gene was used as a negative control. Student's t test, relative to IgG: ns = not significant, $**P \le 0.01$, ***P \leq 0.001. See also Figure S6.




Figure S1. Related to Figure 1. A) mRNA expression of the top 5 scoring TFs in the MRA of the BTSCs dataset, comparing MES versus Non-MES. Student's t test, ***P \leq 0.001. **B)** Two-tailed GSEA showing positive or negative targets for the top 5 TFs in the MRA ranked by their differential expression (MES vs Non-MES).





Figure S2. Related to Figure 2. A) Western blot analysis of ERK and pERK expression in BTSC 233 cells transduced with NF1-GRD expressing lentivirus and stimulated with 10% FBS or 100 ng/ml EGF. α -Tubulin is included as loading control. **B)** Densitometric analysis of western blot in A). **C)** Western blot analysis of active Ras pull down assay in BTSC 233 expressing NF1-GRD or control, in presence or absence of growth factors. **D)** GSEA of Ras-induced oncogenic signature in BTSC 233 MES cells transduced with NF1-GRD expressing lentivirus versus Ctrl.



45

Figure S3. Related to Figure 2. A) Western blot analysis of FLAG-NF1-GRD expression in MES cells (BTSC 233 and 232). **B)** Western blot analysis of NF1 expression upon *NF1* knockdown in PN cells (BTSC 3021 and 3047). **C)** and **D)** qRT-PCR analysis of mesenchymal genes master regulators expression (*BHLHB2, CEBPB, FOSL2, RUNX1, STAT3* and *TAZ*) upon NF1-GRD overexpression in BTSC 233 (C) or *NF1* knockdown in 3021 cells (D). Data are presented as mean \pm SD (n=3), normalized to GAPDH or 18s rRNA expression; Student's t test, ns = not significant, *P \leq 0.05. **E)** GSEA of *FOSL1* targets signature in GBMs with *NF1* alteration or wt status (*top panel*), BTSC 3021 cells transduced with sh*NF1* or shCtrl (*middle panel*), and BTSC 233 cells transduced with NF1-GRD or Ctrl vector (*bottom panel*). **F)** and **G)** qRT-PCR analysis of known mesenchymal *FOSL1* targets (*ITGA3, ITGA5, PLAU, SERPINE1* and *TNC*) in BTSC 233 and 232 cells transduced with NF1-GRD expressing lentivirus (F) and BTSC 3021 and 3047 cells transduced with sh*NF1* expressing lentivirus. Data are presented as mean \pm SD (n=3), normalized to 18s rRNA expression; Student's t test, n= not significant, *P \leq 0.05, *P \leq 0.01, **P \leq 0.001.




Figure S4. Related to Figure 4. Representative images of immunofluorescence staining of the indicated markers in sgCtrl and sg*Fosll*_1 p53-null *Kras^{G12V}* NSCs plated on laminin-coated coverslips. Scale bars represent 50 µm.




Figure S5. Related to Figure 5. A) Kaplan-Meier survival curves of C57BL/6J wildtype mice injected with p53null *Kras*^{G12V} *Fosl1*^{tetON} NSCs subjected to Dox diet (n=8) or kept as controls (n=8); Log-rank P value = 0.814. **B)** Hematoxylin and eosin (H&E) and immunohistochemical staining, using the indicated antibodies, of representative –Dox and +Dox tumors. Scale bars represent 100 µm.




Figure S6. Related to Figure 6. A) BrdU incorporation of BTSC 349 shGFP and sh*FOSL1*, in absence or presence of Dox, analyzed by flow cytometry. Data from a representative of two independent experiments are presented as mean \pm SD (n=3). Student's t test, relative to the respective control (–Dox): ns = not significant, **P \leq 0.01. **B**) mRNA expression of PN genes in BTSC 349 sh*FOSL1* in absence or presence of Dox for 3 days. Data from a representative of three experiments are presented as mean \pm SD (n=3), normalized to *GAPDH* expression. Student's t test, relative to –Dox: ns = not significant, *P \leq 0.05.